INTRODUCTION {#s1}
============

Glioblastoma multiform {#s1_1}
----------------------

Glioblastoma multiform (GBM), WHO grade IV, is the most common and aggressive glioma of all primary brain tumors, exhibiting a high rate of recurrence and poor prognosis due to the invasive nature of the tumor \[[@R1], [@R2]\]. Considering the location and diffusely infiltrating nature of the tumor, complete surgical resections are challenging. Standard therapy for GBM is radiation plus the chemopeutic agent temozolomide (TMZ). The cytotoxicity of TMZ is thought to be primarily due to alkylation of DNA hence leading to DNA damage and tumor cell death \[[@R3]\]. However, the activation of PI3K/Akt/mTOR pathway leads to the development of drug resistance thereby dampening the therapeutic effect of TMZ \[[@R4]\]. The five year survival rate for glioblastoma is less than 5% in adults \[[@R5]-[@R7]\]. The occurrence of GBM is frequently associated with molecular changes in epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathways. The frequency of genetic alterations such as overexpression EGFR, activating mutations of PI3CA (p110) or PIK3R1 (P85), or loss of PTEN expression has been estimated to around 88% \[[@R8]-[@R12]\]. GBM patients with an activated PI3K/Akt/mTOR pathway also have poor prognosis than patients without oncogenic activation of the pathway \[[@R13]\]. Therefore, inhibitors targeting EGFR and PI3K/Akt/mTOR pathway have emerged as potential treatment for GBM \[[@R14]-[@R18]\]. Currently, a series of inhibitors targeting EGFR and PI3K/Akt/mTOR pathway are evaluated in preclinical and clinical studies as single agent or in combination with the traditional treatment \[[@R19]\]. It is of particular interest to explore whether those inhibitors are effective to restore the therapeutic sensitivity.

EGFR and PI3K/Akt/mTOR signal transduction pathway {#s1_2}
--------------------------------------------------

EGFR is a type of receptor tyrosine kinases (RTKs), playing a central role in cell division, migration, adhesion, differentiation and apoptosis \[[@R20], [@R21]\]. EGFR comprises of extracellular ligand binding domain, transmembrane domain and intracellular tyrosine kinase domain. Upon binding to various of ligands, such as EGF and TGFα, EGFR is activated through homodimerization or heterdimerization on the cell surface and subsequently leads to the phosphorylation of its intracellular tyrosine kinase domain \[[@R22]\]. The activation of EGFR results in activation of multiple downstream signal transduction pathways such as PI3K/Akt/mTOR pathway \[[@R23]\].

Members of the PI3K family are lipid kinases involved in multiple cellular process, including proliferation, differentiation, migration, metabolism and survival \[[@R24]\]. PI3K is generally classified into three classes according to their substrate specificity and subsequence homology, among which, the class I is most vital to the tumorigenesis. Class I consisted of a catalytic subunit p110 (α, β, γ) and a regulator subunit p85. A fourth p110 isoform (p110δ) is paired with the p101 regulatory subunit in class IB PI3Ks. Upon ligand binding, phosphorylated tyrosine residing in activated RTKs will bind to p85. The subsequent conformation change will release the catalytic subunit p110 \[[@R25]\], where activated p110 phosphorylated the phosphatidy-linositol-3, 4-bisphosphate (PIP2) into the second messenger phosphatidylinositol-3, 4, 5-bisphosphate (PIP3). This reaction can be reversed by the PI3K antagonist PTEN (phosphatase and tensin homolog deleted on chromosome ten) \[[@R26]\]. Subsequently, PIP3 will recruit the downstream Akt to inner membranes and phosphorylates Akt on its serine/threonine kinasesites (Thr308 and Ser473) \[[@R27], [@R28]\]. Activated Akt is involved in the downstream mTORC1 mediated response to biogenesis of protein and ribosome.

In PI3K pathway, mTOR acts as both a downstream effector and an upstream regulator \[[@R29], [@R30]\]. mTOR resides in rapamycin-sensitive mTOR-complex (mTORC1) and a rapamycin-insensitive complex (mTORC2) \[[@R31], [@R32]\]. The activated Akt inhibits tuberous sclerosis complex (TSC) 1/2 activity, thereby initiate the mTORC1-mediate signaling pathway, involving in the phosphorylation of ribosomal protein S6 kinase (pS6k), eukaryotic initiation factor 4E (eIF4E) and eukaryotic initiation factor binding protein 1(4EBP1), which participate in protein translation, ribosome biogenesis as well as cell growth \[[@R33], [@R34]\]. The mTORC2 phosphorylates Akt at Ser-473, and then further takes part in cell survival, metabolism, proliferation, and cytoskeletal organization \[[@R31], [@R35]\]. Within PI3K signaling pathway, another important molecule is PTEN. As clinical research revealed, the EGFR or PTEN mutation would lead to continuous activation of PI3K/Akt/mTOR signaling pathway, thereby contributing to the tumorigenesis and cancer therapy resistance (Figure [1](#F1){ref-type="fig"}).

![Schematic representation of the PI3K/Akt/mTOR signaling pathway\
Upon relevant ligand binding, RTK, such as EGFR, is activated and subsequently inducing a series of cascade reaction. First, the regulator subunits of PI3K, p85, dimerize and release its catalytic subunit p110. p110 enables the membrane protein PIP2 to phosphorylate into PIP3. PIP3 begins to recruit the downstream Akt to inner membranes and phosphorylated the serine/threonine kinase (Thr308 and Ser473) sites by phosphoinositide-dependent kinase 1/2 (PDK1/2). Activated Akt is involved in the downstream mTORC1 mediated response to biogenesis of protein and ribosome. Besides that, activated Akt is also involved in the regulation of cell cycle and pro-apoptotic and anti-apoptotic factors mediated choices of cell apoptosis and survival. Additionally, it is also involved in the NFκB/MDR1 mediated drug resistance.](oncotarget-07-33440-g001){#F1}

THE DEVELOPMENT OF TARGETED THERAPY TOWARDS EGFR AND PI3K/AKT/MTOR {#s2}
==================================================================

EGFR inhibitors {#s2_1}
---------------

EGFR alteration, including overexpression or gene amplification, is the most frequent form of genetic mutation, occurred in 40-50% of glioblastomas \[[@R36], [@R37]\]. Logically, EGFR is a promising target for the treatment of GBM. Though promising results was shown in preclinical data, targeting EGFR in clinical trials revealed marginal effects. An overview of ongoing clinical trial in GBM is summarized in Table [1](#T1){ref-type="table"}. Information about clinical trials has been retrieved from [www.clinicaltrials.gov](http://www.clinicaltrials.gov/). In the clinical trial NCT00250887, the effectiveness of EGFR tyrosine kinase inhibitor Gefitinib was tested in recurrent glioblastoma. Though EGFR was successfully -dephosphorylated, the downstream target remains constitutively active. Therefore the effectiveness was unsatisfactory \[[@R38]\]. Erlotinib, another selective EGFR inhibitor, also showed minimal effect to treat the recurrent glioblastoma (NCT00086879) \[[@R39]\]. Other than single agent treatment, combination therapy was also explored. When Erlotinib was combined with TMZ and radiotherapy in a phase I/II trial, no sign of benefit was showed compared with TMZ controls (NCT00039494) \[[@R40], [@R41]\]. Additionally, the combination therapy of Erlotinib with VEGF antibody also shows no obvious survival benefit \[[@R42]\]. The failure of targeting EGFR is generally due to the hyperactivation of downstream PI3K/Akt signaling, so the downstream components represents an attractive target for the treatment of malignant brain tumors.

###### Ongoing clinical trials in brain tumors targeting EGFR

  Drug                                   Targets                      Combination Partner                       Patient group                                  Phase       State                Trail ID
  -------------------------------------- ---------------------------- ----------------------------------------- ---------------------------------------------- ----------- -------------------- -------------
  Gefitinib                              EGFR                                                                   recurrent glioblastoma                         II          completed            NCT00250887
  EGFR                                                                GBM                                       II                                             completed   NCT00014170          
  EGFR                                                                GBM                                       II                                             completed   NCT00016991          
  EGFR                                                                brain and central nervous system tumors   II                                             completed   NCT00025675          
  EGFR                                   radiation                    GBM                                       I/II                                           completed   NCT00052208          
  EGFR                                   radiation                    GBM                                       II                                             completed   NCT00238797          
  Gefitinib, Temozolomide                EGFR                                                                   brain and central nervous system tumors        I           completed            NCT00027625
  Gefitinib, Irinotecan                  EGFR, topoismerase I                                                   refractory solid tumor                         I           completed            NCT00132158
  Erlotinib                              EGFR                                                                   GBM                                            II          completed            NCT00337883
  EGFR                                                                GBM                                       II                                             unknown     NCT00054496          
  EGFR                                                                GBM and other brain tumors                I/II                                           ongoing     NCT00045110          
  EGFR                                                                GBM                                       I/II                                           completed   NCT00301418          
  EGFR                                   radiation                    brain/central nervous system tumors       I/II                                           completed   NCT00124657          
  EGFR                                   cytoreductive surgery        recurrent malignant gliomas                                                              ongoing     NCT01257594          
  Erlotinib, Temozolomide                EGFR                         radiation                                 GBM, gliosarcoma                               II          completed            NCT00187486
  EGFR                                   radiation                    GBM                                       II                                             completed   NCT00274833          
  EGFR                                   radiation                    GBM                                       II                                             completed   NCT00039494          
  Erlotinib, Temozolomide, Carmustine    EGFR                                                                   glioblastoma, gliosarcoma                      II          completed            NCT00086879
  Erlotinib, Bevacizumab.                EGFR, VEGF                                                             glioblastoma, gliosarcoma                      II          completed            NCT00671970
  Erlotinib, Bevacizumab, Temozolomide   EGFR, VEGF                   radiation                                 GBM                                            II          ongoing              NCT00720356
  Erlotinib, Sorafenib                   EGFR, RAF, VEGFR                                                       GBM                                            II          completed            NCT00445588
  Erlotinib, Dasatinib                   EGFR, SRC                                                              GBM                                            I           completed            NCT00609999
  Dacomitinib                            EGFR                                                                   recurrent glioblstoma                          II          ongoing              NCT01520870
  Afatinib                               EGFR                                                                   refractory solid tumors                        II          completed            NCT00875433
  AEE788                                 EGFR                                                                   GBM                                            I/II        completed            NCT00116376
  Lapatinib                              EGFR                                                                   GBM                                            I/II        completed            NCT00099060
  Lapatinib                              EGFR                                                                   malignant brain tumors                         II          completed            NCT00107003
  Nimotuzumab                            EGFR                                                                   GBM                                                        completed            NCT00561873
  Nimotuzumab, Temozolomide              EGFR                         radiation                                 GBM                                            III         completed            NCT00753246
  EGFR Bi-armed Autologous T cells       EGFR, CD3                                                              glioblastoma, gliosarcoma recurrent neoplasm   I/II        not yet recruiting   NCT02521090
  AMG 595                                EGFR                                                                   GBM                                            I           ongoing              NCT01475006
  Sym004                                 EGFR                                                                   recurrent glioblastoma                         II          ongoing              NCT02540161
  Cetuximab, Temozolomide                EGFR                         radiation                                 GBM                                            I/II        unknown              NCT00311857
  Cetuximab, Bevacizumab, Irinotecan     EGFR, VEGF, topoismerase I                                             GBM                                            II          completed            NCT00463073
  Afatinib, Temozolomide                 EGFR                         radiation                                 GBM                                            I           ongoing              NCT00977431
  Afatinib, Temozolomide                 EGFR                                                                   GBM                                            II          ongoing              NCT00727506

Clinical data related to the EGFR was searched until Nov, 2015.

PI3K inhibitors {#s2_2}
---------------

Currently, the PI3K inhibitors as a single agent or combined with other therapies are being tested in a number of clinical trials (Table [2](#T2){ref-type="table"}) \[[@R43]\]. There are pan-PI3K inhibitors and isoform specific PI3K inhibitors \[[@R14]\]. The first generation of pan-PI3K inhibitors is represented by wortmannin and LY294002 \[[@R44], [@R45]\]. They have showed anti-cancer effect *in vivo* and *in vitro* \[[@R46]-[@R49]\]. However, both drugs were halted at preclinical studies due to the toxicity, poor pharmacodynamics and selectivity. A new generation of PI3K inhibitors, BKM120 and PX-866, exhibit better drug properties such as high stability and low side effects \[[@R50], [@R51]\]. BKM120 has anti-proliferative and pro-apoptotic activity in a number of tumor cell lines, human tumor xenograft models and cancer patients bearing PI3K activating mutations \[[@R52]\]. BKM120 was smoothly passed phase I clinical trial and now is undergoing phase II trial among patients with recurrent glioblastoma and activated PI3K pathway (NCT01339052) (Table [2](#T2){ref-type="table"}) \[[@R50]\]. At present, BKM120 is also undergoing several clinical trials in combination with radiation (NCT01473901), anti-VEGF monoclonal antibody Bevacizumab (NCT01349660), LDE225 (NCT01576666) and INC280 (NCT01870726) \[[@R53]\]. PX-866 could bind with the catalytic domain of ATP and it acts as an irreversible inhibitor. Though PX-866 could increase median survival time of the animals and show significant anti-tumor activity in GBM xenograft models \[[@R54], [@R55]\], the recent completed clinical study showed the overall response rate was low (NCT01259869) \[[@R56]\].

###### Ongoing clinical trials in brain tumors targeting PI3K

  Drug                   Targets                   Combination partner   Patient group            Phase         State       Trail ID
  ---------------------- ------------------------- --------------------- ------------------------ ------------- ----------- -------------
  BKM120                 Pan-PI3K                  surgery               recurrent glioblastoma   II            ongoing,    NCT01339052
  Bevacizumab            relapsed/refractory GBM   I/II                  recruiting               NCT01349660               
  LDE225                 advanced solid tumor      I                     completed                NCT01576666               
  INC280                 recurrent glioblastoma    I/II                  recruiting               NCT01870726               
  BKM120, Temozolomide   Pan-PI3K                  radiation             glioblastoma             I             ongoing     NCT01473901
  PX-866                 Pan-PI3K                                        GBM                      II            completed   NCT01259869

Clinical data related to the EGFR was searched until Nov, 2015.

Akt inhibitors {#s2_3}
--------------

Akt is a central player in the EGFR/PI3K signaling pathways. Evidence shows that Akt play an important role in tumor proliferation and radiosensitivity \[[@R57]\]. One of the most promising Akt inhibitor, perifosine, inhibits Akt activity by preventing its translocation to the cell membrane \[[@R58], [@R59]\]. Currently, perifosine is being clinically tested in a number of different cancers \[[@R60], [@R61]\]. Perifosine has several drawbacks such as limited ability to penetrate blood-brain-barrier (BBB) and gastrointestinal side effects. A phase II trial of perifosine in recurrent GBM was ongoing but only marginal effect was shown (NCT00590954).

mTOR inhibitors {#s2_4}
---------------

As downstream targets of phosphorylated Akt, inhibition of mTOR would also be another therapeutic approach to reduce the effects of constitutively activate Akt in GBM. mTORC1 inhibitors mainly contain rapamycin (sirolimus) and its analogues, such as RAD001 (everolimus), CCL-779 (temsirolimus) and AP23573 (ridaforolimus) \[[@R62]\]. Rapamycin inactivate mTORC1 through altering the conformation of the kinase. Though rapamycin and its analogues exhibit efficacy of mTOR inhibitors in both *in vitro* and *in vivo* models \[[@R63], [@R64]\], they would arose hyperactivation of Akt and mTORC2 by some feedback loop and pathway crosstalk \[[@R65]\]. Rapamycin shows anti-tumor activity in a phase I trial for patients with recurrent PTEN-deficient glioblastoma (NCT00047073) \[[@R66]\]. Unfortunately, phase II clinical trials for rapamycin analogs fail to achieve promising results (NCT00515086, NCT00016328, NCT00022724, and NCT00087451) \[[@R67]-[@R71]\]. The limited efficacy might result from the feedback loops and crosstalk with other pathways. Recently, more exploration was focusing on the combination treatment of rapamycin analogs with other modalities \[[@R71]\]. The combination of EGFR inhibitor erlotinib with sirolimus or temsirolimus was tested in clinical trials (NCT00112736 and NCT0062243). However, either of trial shows promising results \[[@R72], [@R73]\]. A phase II study of everolimus with bevacizumab as part of first-line modality therapy for glioblastoma was feasible and efficacious (NCT00805961) \[[@R74]\], further studies are still need. As combined inhibition of Akt and mTOR by perfosine and temsirolimus inhibited murine glioblastoma growth no matter PTEN status, a phase I/II trial in recurrent high-grade gliomais ongoing (NCT01051557) \[[@R75], [@R76]\]. Metformin is a widely prescribed antidiabetic drug and many studies indicate that metformin inhibits cancer proliferation through the inhibition of mTOR \[[@R77]\]. The efficacy of metformin on glioblastoma was tested in clinical trial NCT01430351 and NCT02149459. In NCT02149459, metformin was combined with radiotherapy. In NCT01430351, metformin was combined with TMZ. Both of the trials are still in phase I state.geting specifically mTORC2 could thereby be a better approach, since it would directly block Akt phosphorylation without perturbing the mTORC1-dependent feedback loops \[[@R78], [@R79]\]. In contrast to mTORC1, mTORC1/2 inhibitors can restrain Akt phosphorylation at Ser473, thus also inhibit mTORC2 at the same time \[[@R63]\]. AZD8055 is a potent small molecular ATP-competitive inhibitor. *In vivo*, AZD-8055 reduced S6 and Akt phosphorylation thereby leading to the reduction of tumor growth \[[@R80]\]. It is implicated that AZD8055 may provide a more promising therapeutic strategy than rapamycin and analogues \[[@R81]\]. Currently AZD8055 has completed the phase I clinical trials (NCT01316809).

PI3K/mTOR dual inhibitor {#s2_5}
------------------------

Since mTORC1 inhibitors could induce the loss of feedback inhibition of PI3K activation, drugs targeting PI3K and mTOR kinase simultaneously thereby become a superior option \[[@R82]\]. Active site ATP-competitor is a class of dual PI3K-mTOR inhibitor, which structurally targets the kinase domains of both PI3K and mTOR. PI-103 was the first dual mTOR/PI3K inhibitors that inhibited mTOR in an ATP-competitive manner \[[@R83]\]. *In vivo* study showed that PI-103 led to G0-G1 cell cycle arrest thereby inhibiting the proliferation and invasion of tumor cells \[[@R84]\]. However, PI-103 was halted in the preclinical period due to the poor pharmacokinetic properties. NVP-BEZ235 is a promising PI3K/mTOR dual inhibitor exhibiting improved anti-tumor potential compared to rapamycin analogs \[[@R85]-[@R88]\]. In preclinical test, study demonstrated that NVP-BEZ235 significantly prolonged the survival of tumor bearing animals without eliciting obvious toxicity \[[@R89]\]. Therefore, NVP-BEZ235 has entered phase I and phase II clinical trials with everolimus in patients with malignant solid tumors (NCT01508104). Other dual PI3K and mTOR inhibitors, such as PKI-587 and XL-765, have shown favorable activity in preclinical settings. XL-765 has completed the trial in combination with radiotherapy and TMZ for GBM as well as in subjects with recurrent GBM (NCT00704080). PKI-587 and XL-765 have recently completed the phase I clinical trials for the treatment of solid tumors (NCT00940498) and recurrent GBM who are candidates for surgical resection (NCT01240460).

THE LIMITED FACTORS OF TARGETED THERAPY BASED ON PI3K SIGNALING PATHWAY {#s3}
=======================================================================

Though more and more PI3K/Akt/mTOR targeted drugs emerge, they are still undergoing preclinical or clinical trials. Targeted therapy for GBM has yet to demonstrate an appreciable clinical survival benefit. At present, here are some possible reasons for the limited therapy effect: (1) Blood Brain Barrier. It\'s the most likely explanation for why targeted drugs cannot reach effective concentrations (2) Heterogeneity of GBM. No doubt the outcome of drug efficacy is much influenced by the genetic background of the tumor. In malignant tumors, molecular phenotype of the same tumor in different location may totally diverse and molecular phenotype of the same tumor in different people may also vary. Thereby the sensitivity to targeted therapy may vary. (3) The activation of alternative pathways leads to immune escape. In clinical trials, only a small proportion of the clinical trials in malignant gliomas concurrently conducted pharmacokinetic studies and most of these studies collect blood samples to work out plasma clearance, rather than directly analysis of cerebrospinal fluid or drug concentration in tumor tissues. Collectively, there are all relevant restrictions to targeted therapy based on PI3K signal pathway.

###### Ongoing clinical trials in brain tumors targeting mTOR.

  Drug                                                 Targets                                   Combination Partner        Patient group                                   Phase         State        Trail ID
  ---------------------------------------------------- ----------------------------------------- -------------------------- ----------------------------------------------- ------------- ------------ -------------
  Sirolimus                                            mORC1                                                                GBM                                             I/II          completed    NCT00047073
  vaccine therapy                                      NY-ESO-1 expressing solid tumors          I                          ongoing                                         NCT01522820                
  Sirolimus, Erlotinib                                 mTORC1 +EGFR                                                         glioblastoma                                    II            completed    NCT00672243
                                                       malignant glioma                          I/II                       completed                                       NCT00509431                
  Sirolimus, Vandetanib                                mTORC1 +VEGF                                                         glioblastoma                                    I             completed    NCT00821080
  Everolimus, Temozolomide                             mTORC1                                                               GBM                                             I             completed    NCT00387400
  radiation                                            GBM                                       I/II                       ongoing                                         NCT01062399                
  radiation                                            glioblastoma                              I/II                       ongoing,                                        NCT00553150                
  Everolimus, Gefitinib                                mTORC1+ EGFR                                                         progressive GBM                                 I/II          completed    NCT00085566
  Everolimus, Gleevec, Hydroxyurea                     mTORC1, PDGFR BCR-AbI                                                                                                I             completed    NCT00613132
  Everolimus, Temozolomide Bevacizumab                 mTORC1, VEGF                              radiation                  GBM                                             II            completed    NCT00805961
  Everolimus, AEE788                                   mTORC1, EGFR, VEGFR                                                  GBM                                             I/II          completed    NCT00107237
  Everolimus, BEZ235                                   mTOR, PI3K/mTOR                                                      Cancer                                          I/II          unknown      NCT01508104
  Everolimus, Sorafenib                                mTORC1, RAF                                                          recurrent high-grade gliomas                    I/II          recruiting   NCT01434602
  Temsirolimus                                         mTORC1                                                               brain and central nervous system tumors         I             completed    NCT00784914
                                                       brain and central nervous system tumors   I/II                       completed                                       NCT00022724                
                                                       GBM                                       II                         completed                                       NCT00016328                
  Temsirolimus, Doxorubicin                            mTORC1                                                               resistant solid malignancies                    I             completed    NCT00703170
  Temsirolimus, Docetaxel                              mTORC1                                                               resistant solid malignancies                    I             completed    NCT00703625
  Temsirolimus, Temozolomide,                          mTORC1                                    radiation                  GBM                                             I             completed    NCT00316849
  glioblastoma                                         II                                        ongoing                    NCT01019434                                                                
  Temsirolimus, Sorafenib, Erlotinib, Tipifarnib       mTORC1 +EGFR                                                         recurrent GBM or gliosarcoma                    I/II          completed    NCT00335764
  Temsirolimus, Erlotinib,                             mTORC1 +EGFR                                                         recurrent malignant glioma                      I/II          completed    NCT00112736
  Temsirolimus, Perifosine                             mTORC1, +Akt                                                         malignant gliomas                               I/II          ongoing      NCT01051557
  cytoreductive surgery, Immuno-suppressant            brain tumor                               II                         recruiting                                      NCT02238496                
  Temsirolimus, Bevacizumab                            mTORC1 +VEGF                                                         GBM                                             II            completed    NCT00800917
  Ridaforolimus                                        mTOR                                                                 Glioma                                          I             completed    NCT00087451
  CC-115                                               DNA-PK/mTOR                                                          advanced solid tumor                            I/II          ongoing      NCT01353625
  CC-223                                               dual mTOR inhibitor                       surgery, supportive care   advanced solid tumor                            I/II          ongoing      NCT01177397
  XL765, Temozolomide                                  dual PI3K/mTOR                            radiation                  GBM                                             I             completed    NCT00704080
  XL147, XL765                                         PI3K, PI3K/mTOR                                                      glioblastoma, astrocytoma, Grade IV             I             completed    NCT01240460
  PKI-587                                              PI3K, class IA, mTORC1/C2                                            solid tumor                                     I             completed    NCT00940498
  AZD8055                                              mTOR                                                                 GBM                                             I             completed    NCT01316809
  INK128                                               mTORC1/2                                  Bevacizumab                recurrent glioblastoma, advanced solid tumors   I             recruiting   NCT02142803
  Pembrolizumab, Pictilisib, NVP-BEZ235, Ipatasertib   PI3Kα/δ, PI3K/mTOR, Akt1/2/3                                         Glioblastoma                                    I/II                       NCT02430363
  Metformin Temozolomide                               mTOR                                                                 GBM                                             I             ongoing      NCT01430351
  Metformin                                            mTOR                                      radiation                  recurrent brain tumor                           I             recruiting   NCT02149459

Clinical data related to the EGFR was searched until Nov, 2015.

CONCLUSION AND FUTURE PROSPECTS {#s4}
===============================

As we have discussed here, PI3K/Akt/mTOR signal pathway after activation of EGFR is one of the most significant signal pathways in tumor cells. It has confirmed that it plays an important role in the genesis and development of glioma. At the moment, targeted therapy towards intracellular signal pathways has not achieved satisfactory result yet. A future perspective for GBM therapy is combination of multiple targets and personalized treatment. Although issues like cross-talk signal pathways or tumor heterogeneity tarnished the efficacy of therapy targeted PI3K/Akt/mTOR as we expected, we still believe that it will light up a new way in glioblastoma therapy. Recent study showed that targeting HSP90 and histone deacetylases could enhance the therapeutic effect of TMZ combined with radiotherapy \[[@R90]\].
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